Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Wave Life Sciences Ltd. - Ordinary Shares (NQ:WVE)

5.510 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,550
Open 5.510
Bid (Size) 5.550 (700)
Ask (Size) 5.590 (100)
Prev. Close 5.510
Today's Range 5.510 - 5.510
52wk Range 5.020 - 21.73
Shares Outstanding 98,983,261
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Wave Life Sciences (WVE) Q2 2026 Earnings Call Transcript ↗
WVE-007 obesity candidate shows 16.5% visceral fat improvement in early trials. 
Via The Motley Fool
Topics Earnings
News headline image
WAVE Life Sciences Q2 Earnings Call Highlights ↗
WAVE Life Sciences (NASDAQ:WVE) reported a wider second-quarter loss as it increased investment in its obesity and RNA-editing programs, while outlining several clinical and regulatory milestones... 
Via MarketBeat
Topics Earnings

Performance

YTD
-65.5%
-65.5%
1 Month
-12.8%
-12.8%
3 Month
-26.2%
-26.2%
6 Month
-59.0%
-59.0%
1 Year
-37.0%
-37.0%

More News

Read More
Wave Life Sciences (NASDAQ:WVE) Plunges After Q2 Revenue Miss ↗
Via Chartmill
News headline image
Wave Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Wave Life Sciences (NASDAQ:WVE) Beats Q1 Estimates as Obesity Program Accelerates ↗
Via Chartmill
News headline image
Wave Life Sciences Second Quarter 2026 Financial Results Scheduled for July 30, 2026
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Wave Life Sciences Announces Singapore Court Hearing, to be held on July 14, 2026 to Approve Scheme of Arrangement for Redomiciliation
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Wave Life Sciences Announces Initiation of Phase 2a Portion of INLIGHT™ Trial of WVE-007 (INHBE GalNAc-siRNA) for Obesity and Cardiometabolic Diseases
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Wave Life Sciences to Present at Upcoming Investor Conferences
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
This $5.5 Million Exit Raises Questions After Wave Life Sciences' Rough First Quarter ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Wave Life Sciences Announces Positive Update on RestorAATion-2 Trial: WVE-006 (GalNAc-RNA Editing) Achieves MZ-Like Phenotype Across Both Biweekly and Monthly Dosing
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Wave Life Sciences to Present at 2026 RBC Capital Markets Global Healthcare Conference
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Wave (WVE) Q1 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Wave (WVE) Q2 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Wave (WVE) Q1 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Wave Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Leads Shift Toward Pipeline-Driven Valuation in Biotech Sector
Via Investor Brand Network
Topics Intellectual Property
Advancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial Recognition
Via Investor Brand Network
News headline image
Wave Life Sciences First Quarter 2026 Financial Results Scheduled for April 28, 2026
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Advancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial Recognition
From BioMedWire
Via GlobeNewswire
News headline image
Wave Life Sciences Announces Hearing on Proposed Redomiciliation to the United States
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Wave Life Sciences Announces Proposed Redomiciliation to the United States
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Is This Weight Loss Drug Stock a Buy on the Dip? ↗
Via The Motley Fool
News headline image
Stock Market Today, March 26: Wave Life Sciences Plunges After High Dose Obesity Drug Data Disappoints ↗
Via The Motley Fool
Topics Stocks
Top movers analysis one hour before the close of the markets on 2026-03-26: top gainers and losers in today's session. ↗
Via Chartmill

Frequently Asked Questions

Is Wave Life Sciences Ltd. - Ordinary Shares publicly traded?
Yes, Wave Life Sciences Ltd. - Ordinary Shares is publicly traded.
What exchange does Wave Life Sciences Ltd. - Ordinary Shares trade on?
Wave Life Sciences Ltd. - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Wave Life Sciences Ltd. - Ordinary Shares?
The ticker symbol for Wave Life Sciences Ltd. - Ordinary Shares is WVE on the Nasdaq Stock Market
What is the current price of Wave Life Sciences Ltd. - Ordinary Shares?
The current price of Wave Life Sciences Ltd. - Ordinary Shares is 5.510
When was Wave Life Sciences Ltd. - Ordinary Shares last traded?
The last trade of Wave Life Sciences Ltd. - Ordinary Shares was at 07/31/26 04:00 PM ET
What is the market capitalization of Wave Life Sciences Ltd. - Ordinary Shares?
The market capitalization of Wave Life Sciences Ltd. - Ordinary Shares is 545.40M
How many shares of Wave Life Sciences Ltd. - Ordinary Shares are outstanding?
Wave Life Sciences Ltd. - Ordinary Shares has 545M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.